PSCA CAR Vδ1 T cells: a safer off-the-shelf CAR T therapy for pancreatic cancer?
Joseph A Fraietta, Jason J Lohmueller · 2026
Read PSCA CAR Vδ1 T cells: a safer off-the-shelf CAR T therapy for pancreatic cancer? by Joseph A Fraietta, Jason J Lohmueller (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13157800.txt.
Description
Joseph Fraietta and Jason Lohmueller comment on a new cell therapy for pancreatic cancer in a 2026 article. The cancer is among the deadliest, and engineered T cell therapy offers hope but can trigger severe side effects.
The study under discussion built its therapy from a rare T cell type that does not need matching tissue markers. In lab models it killed tumors as well as standard engineered cells. Unlike the standard cells, it caused none of the graft-versus-host harm that donor cells can bring. It also tired less than a sibling cell type and survived freezing well, a must for off-the-shelf use. The authors of the commentary urge careful clinical trials.
Catalog record
| CREATOR | Joseph A Fraietta, Jason J Lohmueller |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 13 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |